| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Departments of Microbiology/Immunology and Otolaryngology-Head and Neck Surgery, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107; and
Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA 19104
RET/PTC3 (RP3) is an oncogenic fusion protein which is frequently expressed in papillary thyroid carcinomas and has been detected in thyroid tissue from patients diagnosed with Hashimoto’s thyroiditis. The constitutive activation of the tyrosine kinase domain in the carboxyl-terminal end of RP3 induces signaling pathways within thyrocytes and causes cellular transformation. One of the signaling pathways activated in RP3-expressing cells involves the activity of the transcription factor NF-
B and the production of downstream targets including GM-CSF and macrophage chemotactic protein 1. These factors are known to be immunostimulatory, making RP3 a molecular adjuvant and potentially promoting tissue-specific immunity. However compelling, these in vitro data do not reliably predict gene function in vivo or the cumulative effects of time-dependent processes such as angiogenesis, inflammation, or the influence of genetic background. To address these issues, we analyzed the production of proinflammatory mediators in mouse thyroid organs and demonstrate consistency with in vitro studies performed previously that Il1
, Il1
, Il6, and Tnf and the enzyme Cox2 are produced by RP3-transgenic thyroid tissue, but absent from nontransgenic thyroids. Furthermore, we find that that the genetic background of the host is important in the observed RP3-induced inflammation and tumor progression. These findings provide support for the notion that oncogene-induced cytokine secretion is important for the development and progression of thyroid carcinomas in genetically permissive hosts.
This article has been cited by other articles:
|
|
 |
|
  R. Flavin, G. Jackl, S. Finn, P. Smyth, M. Ring, E. O'Regan, S. Cahill, K. Unger, K. Denning, Jinghuan Li, et al. RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma International Journal of Surgical Pathology, June 1, 2009; 17(3): 187 - 197. [Abstract] [PDF]
|
|
|
|
 |
|
 J. S. Pufnock and J. L. Rothstein Oncoprotein Signaling Mediates Tumor-Specific Inflammation and Enhances Tumor Progression J. Immunol., May 1, 2009; 182(9): 5498 - 5506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mantovani Cancer-related Inflammation: The Seventh Hallmark of Cancer ASCO Educational Book, January 1, 2009; 2009(1): 723 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Burniat, L. Jin, V. Detours, N. Driessens, J.-C. Goffard, M. Santoro, J. Rothstein, J. E. Dumont, F. Miot, and B. Corvilain Gene Expression in RET/PTC3 and E7 Transgenic Mouse Thyroids: RET/PTC3 But Not E7 Tumors Are Partial and Transient Models of Human Papillary Thyroid Cancers Endocrinology, October 1, 2008; 149(10): 5107 - 5117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Finn Cancer Immunology N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gasparre, A. M. Porcelli, E. Bonora, L. F. Pennisi, M. Toller, L. Iommarini, A. Ghelli, M. Moretti, C. M. Betts, G. N. Martinelli, et al. Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors PNAS, May 22, 2007; 104(21): 9001 - 9006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Santoro, R. M. Melillo, and A. Fusco RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur. J. Endocrinol., November 1, 2006; 155(5): 645 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mesa Jr., M. Mirza, N. Mitsutake, M. Sartor, M. Medvedovic, C. Tomlinson, J. A Knauf, G. F. Weber, and J. A. Fagin Conditional Activation of RET/PTC3 and BRAFV600E in Thyroid Cells Is Associated with Gene Expression Profiles that Predict a Preferential Role of BRAF in Extracellular Matrix Remodeling. Cancer Res., July 1, 2006; 66(13): 6521 - 6529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Rhoden, K. Unger, G. Salvatore, Y. Yilmaz, V. Vovk, G. Chiappetta, M. B. Qumsiyeh, J. L. Rothstein, A. Fusco, M. Santoro, et al. RET/Papillary Thyroid Cancer Rearrangement in Nonneoplastic Thyrocytes: Follicular Cells of Hashimoto's Thyroiditis Share Low-Level Recombination Events with a Subset of Papillary Carcinoma J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2414 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Weber, S. E. Choe, K. A. Dooley, N. N. Paffett-Lugassy, Y. Zhou, and L. I. Zon Mutant-specific gene programs in the zebrafish Blood, July 15, 2005; 106(2): 521 - 530. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
